Recently, Lindmik Pharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as "Lindmik Pharmaceutical") announced the completion of nearly 100 million yuan of financing. This round is led by CICC Private Equity, followed by Chengming Capital, with strong support and friendly cooperation from old shareholders Fuhui Venture Capital and Ruihe Capital. This round of financing will help the company to develop, produce and register innovative preparations, and focus on accelerating the commercial production and market promotion of two core products, flurbiprofen gel paste and loxoprofen sodium gel paste.

Lindmik Pharmaceutical (Suzhou) Co., Ltd. was established in 2019 and is a leading platform enterprise in China that focuses on the field of transdermal drug delivery. The company has built a research and development technology platform including Cataplasms (gel patch), Tape (hot-melt adhesive patch) and Patch (solvent adhesive patch), has a number of invention patents around transdermal drug delivery, and has introduced a number of imported precision production lines, with a large-scale commercial production capacity of 500 million tablets per year. Two core products, flurbiprofen gel patch and loxoprofen sodium gel patch, have taken the lead in the review phase of supplementary materials, and are expected to be approved as the first. Flurbiprofen gel plaster and loxoprofen sodium gel plaster are currently produced exclusively by Taide Pharmaceutical and Jiudian Pharmaceutical (300705) under China Biopharmaceutical (1177. HK) respectively, with a total market size of more than 5 billion yuan and still growing at a high speed.

Mr. Gu Danhui, Chairman of Lindmik Pharmaceutical, stated that there is a huge clinical unmet demand in the field of transdermal drug delivery. The current market size is large, the growth rate is fast, and the future potential is unlimited. At the same time, the research and development barrier is high, the preparation process is complex, and commercial production is difficult, making it a platinum track with long slopes and thick snow. Leming Pharmaceutical is currently in an important milestone stage of transformation from R&D driven to comprehensive commercialization. We are very grateful for the trust and support of new and old shareholders. In the field of transdermal drug delivery, we not only have strong research and development capabilities, but also have complete production and sales capabilities. We are confident in quickly promoting product approval and commercialization, and look forward to witnessing the growth and transformation of Luming together with everyone!

CICC Private Equity Investment Management Co., Ltd. (referred to as "CICC Private Equity") is a wholly-owned private equity fund subsidiary established by China International Finance Corporation ("CICC") in Shanghai, approved by relevant regulatory authorities. It mainly manages private equity funds registered in the Yangtze River Delta region within the CICC system, committed to serving the development of the real economy in the Yangtze River Delta region and supporting the integrated development strategy of the Yangtze River Delta.

Beijing Chengming Private Equity Fund Management Co., Ltd. (referred to as "Chengming Capital") is a professional private equity investment institution that mainly invests in big health and industry. It has built an ecological platform of "industry, investment, politics, and research", and the investment team members have more than 10 years of investment experience in related industries. The core personnel have an international perspective and have invested in healthcare and technology in North America and China. They have led over ten equity funds with a total scale of over 5 billion yuan.

Founded in 2008, Fuhui Venture Capital focuses on early investment in scientific and technological achievements transformation, incubates a number of scientific and technological achievements of the Chinese Academy of Sciences and outstanding early technology enterprises, and provides continuous investment support to the invested enterprises. In recent years, Fuhui Venture Capital has launched in-depth strategic cooperation with the Chinese Academy of Sciences Shanghai Institute of Materia Medica and the Zhongshan Municipal Government to set up a pharmaceutical industry investment fund, focusing on innovative drugs, high-end preparations and CXO direction. At present, it has invested in dozens of leading enterprises in the industry, and is committed to promoting the rapid development of more high-quality innovative drugs, high-end preparations and other enterprises to benefit mankind.

Ruihe Capital was founded by senior industry and financial professionals in 2010, with the mission of "helping enterprises innovate and grow, promoting industrial optimization and upgrading, and promoting social development and progress". It focuses on early and medium-term investment in the fields of intelligent technology and life and health. In terms of life and health, Ruihe Capital has led investments in excellent enterprises such as Minova, Titan Technology, Arno Pharmaceuticals, Huaxian Pharmaceutical, Zhihe Biotechnology, Meike Medicine, and Leming Pharmaceutical.